Author: Ryan Allway

VANCOUVER, British Columbia, June 12, 2018 (GLOBE NEWSWIRE) — CROP Infrastructure Corp. (CSE:CROP) (OTCMKTS:CRXPF) (“CROP” or the “Company”) is pleased to announce it has signed a definitive licensing agreement for US distribution rights and for the exclusive Italian rights to The Yield Growth Corp.’s proprietary cosmetic and therapeutic products that are formulated for infusion with cannabis.

The agreement grants CROP the license to infuse Yield Growth subsidiary Juve Wellness Inc.’s products with high CBD / low THC cannabis and exclusively distribute the products in Italy for three years, with  annual renewals on achieving certain sales. Juve has agreed to customize branding and labelling of its products for CROP for the Italian market.

CROP is also acquiring the non-exclusive rights to distribute the line of hemp root oil based Juve products in the United States.   Juve and CROP have agreed to negotiate exclusively for a period of 30 days for the possible exclusive rights to infuse the products with cannabis and distribute them in California and Washington.

Juve has developed a modern wellness line inspired by Ayurveda, an ancient and effective medical system that uses plant based ingredients for healing and wellness. Juve has registered 25 of its products with Health Canada and has submitted 10 provisional patent applications in the United States for its formulas and extraction process.  Juve plans to launch its products for Canadian retail distribution in early 2019.  The line includes over 50 cosmetic and therapeutic products based on proprietary completely organic formulations which have been designed to be infused with Cannabidiol (CBD) and Tetrahydrocannabinol (THC).  The line includes face and body products customized according to specific body biology, including daily ritual oils, moisturizers, face mists, bath salts, soap and face masks.  Therapeutic products include sunscreen, anti-aging serum, topical formulations for treatment of inflammation and chronic pain, sports spray, teas and capsules.  Sexual lubricant, massage oils, lip balm, deodorant and sunscreen are also included in the CROP licensing package.

According to a study by Arcview Market Research and its research partner BDS Analytics, by 2027 worldwide sales of legal cannabis are forecast to reach $57 billion. During that period, spending in North America is expected to leap from $9.2 billion to $47.3 billion driven mainly by recreational use. The fastest cannabis market growth is expected to come from outside North America, especially Europe where the main growth driver will be medical applications.  Medical cannabis use will be fed by $1.3 trillion estimated annual government-subsidized healthcare spending. The structure of the healthcare industry is expected to make Europe the number one medical cannabis market in the world.

“We are thrilled to be aligned with CROP Infrastructure Corp. to infuse with cannabis and distribute our extensive line of wellness products throughout Italy,” says Penny Green, President and CEO of Yield Growth. “CROP is at the forefront of the burgeoning Cannabis industry as it now seeks to move beyond the State of Washington and California with this deal as its entry into the European cannabis market.”

Michael Yorke, CEO of CROP Infrastructure stated, “This acquisition will be complementary to our efforts of expanding our operations into Europe. We also look forward to bringing this suite of new offerings to our tenant growers and their distribution in Washington and California and as we continue to expand into other States.”

Under the terms of the agreement, Yield Growth will receive $1 million for the Italian license and distribution rights through the issuance of 2,500,000 units of CROP at a deemed price of $0.40 per unit.  Each unit will consist of one common share of CROP and one half warrant to purchase one additional common share at an exercise price of $0.55 per share for eighteen months. The shares will be subject to escrow provisions which will release the stock over a period of three years. In addition to the $1 million unit issuance to Yield Growth, CROP intends to complete a private placement for $200K worth of additional units to pay for marketing expenses.

About The Yield Growth Corp.

The Yield Growth Corp. is a wellness asset growth company cultivating high value companies, brands and assets centered around the legal cannabis industry and its key players. Yield Growth is committed to providing a highly personalized, informed and value-added customer experience within the wellness industry. Yield is a partially owned subsidiary of Glance Technologies Inc. (CSE:GET) (OTCQB:GLNNF) (FKT:GJT).

For more information about The Yield Growth Corp., visit yieldgrowth.com or contact info@yieldgrowth.com.

About CROP Infrastructure Corp.

CROP Infrastructure Corp. is engaged in the business of investing, constructing, owning and leasing greenhouse projects as part of the provision of turnkey real estate solutions for lease-to-licensed cannabis producers and processors offering best-in-class operations. CROP’s portfolio of projects includes greenhouse facilities in California and Washington State.

For more information about CROP Infrastructure Corp.

Michael Yorke – Director
E-mail: info@cropcorp.com
Phone: (604) 484-4206

Disclaimer for Forward-Looking Information
Certain statements in this press release are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events, and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the purchase, development and leasing of projects, commencement of construction of additional greenhouses, estimated Tenant production of product, the pursuit of new opportunities and the expansion of CROP’s portfolio. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding the Company’s ability to execute on its business plan, raise additional funds as and when required, legal and political risks regarding the cannabis industry, including the changes of municipal, state, provincial and federal laws thereof, the risk that Humboldt may require further capital to execute on its expansion plans and other factors beyond the control of the Company. Such forward-looking statements should therefore be construed in light of such factors, and the Company is not under any obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Source: GlobeNewswire (June 12, 2018 – 8:30 AM EDT)

please contact: Speakeasy Cannabis Club Ltd., www.speakeasygrowers.com, Telephone: 604-283-1722Copyright CNW Group 2018

Source: Canada Newswire (June 11, 2018 – 4:05 PM EDT)

TORONTO, June 11, 2018 (GLOBE NEWSWIRE) — The Green Organic Dutchman Holdings Ltd. (the “Company” or “TGOD”) (TSX:TGOD) (US:TGODF) is pleased to announce that, effective June 8^th, its wholly-owned subsidiary, Medican Organic Inc. has received its Cultivation License from Health Canada for the Company’s breeding facility in Salaberry-de-Valleyfield, Quebec (“Valleyfield”). The commissioning of this facility will allow the Company to create proprietary, organically grown strains of cannabis and cannabis seeds.

Located on a 72-acre property, the breeding building will house the cultivation of cannabis and the production of seeds and new strains. This building marks TGOD’s first facility in Valleyfield, which will be followed by the addition of TGOD’s flagship 820,000 square foot state-of-the-art hybrid grow facility, which, when complete, will bring TGOD’s domestic production to 116,000 kgs of high-quality, premium organic cannabis annually. Construction of TGOD’s hybrid facility commenced in early 2018, and to date, site-clearing and earthworks have been completed. To view progress, please visit: https://tgod.ca/.

The history and cultivation of cannabis as a crop has resulted in significant limitations on the research of the plant and its development as an agricultural crop. With the changing regulatory landscape, there is a dramatic need to improve current agronomic traits in the different cannabis strains available to and in the possession of Licensed Producers.

Breeding has many different applications and there are several reasons why TGOD plans to engage in a genetic breeding process, while focusing on growing new cannabis strains specifically tailored for specific medical and commercial uses. The various applications include:

1. Improving the traits of existing strains;
2. Creating new strains by identifying which cannabinoids lead to certain benefits, and then breeding plants that have specific cannabinoid profiles, resulting in potentially patentable products;
3. Creating strains that, because of their genetic characteristics, are better suited to certain environmental conditions than others;
4. Increasing the levels of specific cannabinoids. Specific cannabinoids have been proven to have beneficial effects on certain medical conditions, highlighting the need to advance breeding efforts focused on creating strains rich in cannabinoids such as CBD, GBC and THCV. While for many decades breeders have focused on increasing THC levels, the scientific research demonstrating the medicinal properties of CBD has resulted in an increased demand for high CBD strains;
5. Increasing pest and disease resistance to reduce crop loss;
6. Aiming to reduce flowering duration, creating direct profitability improvements by increasing the number of harvest per year; and
7. Stabilizing genetics in order to produce F1 seeds which will enable plant production directly through seeds as are used in crops such as tomato, cucumber and pepper. This will provide an alternate means to cloning for the growing of this crop.

“One of the biggest gaps in the cannabis industry is the stabilization of genetics through modern breeding techniques, a process that is carried out with most agricultural crops. TGOD’s breeding facility will implement marker-assisted selective breeding to improve traits in cannabis, such as disease resistance to reduce the industry need to rely on pesticides. Improving the plant architecture and flower structure will allow for better mechanization of the harvesting process,” said David Bernard-Perron, Vice President, Growing Operations.

“TGOD’s focus on R&D in the area of breeding and plant genetics will further position the Company as a global industry leader. This technology will enable the Company to produce its own high quality organic cannabis seeds and starting material, which TGOD intends to leverage in its international operations. We are very excited to be focusing our efforts on this important area of innovation which will lead to more tailored strain compositions and a more customized premium product for patients and users,” said Robert Anderson, Co-Chairman and CEO.

On Behalf of the Board of Directors,

The Green Organic Dutchman Holdings Ltd.
Robert Anderson
Chief Executive Officer and Co-Chairman

ABOUT THE GREEN ORGANIC DUTCHMAN HOLDINGS LTD.

The Green Organic Dutchman Holdings Ltd. is a research & development company licensed under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”) to cultivate medical cannabis. The Company carries out its principal activities producing cannabis from its facilities in Ancaster, Ont., pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada) and its regulations.

The Company grows high quality, organic cannabis with sustainable, all-natural principles. TGOD’s products are laboratory tested to ensure patients have access to a standardized, safe and consistent product. TGOD has a funded capacity of 116,000 kg and is building 970,000 sq. ft. of cultivation facilities in Ontario and Quebec.

The Company has developed a strategic partnership with Aurora Cannabis Inc. (TSX:ACB) whereby Aurora has invested approximately C$78.1 million for an approximate 17.5% stake in TGOD. In addition, the Company has raised approximately C$315 million dollars and has over 5,000 shareholders.

TGOD’s Common Shares and warrants issued under the indenture dated November 1, 2017 trade on the TSX under the symbol “TGOD” and “TGOD.WT”, respectively.

CONTACT INFORMATION

Investor Relations
Email: invest@tgod.ca
Phone: 1 (416) 900-7621

www.tgod.ca

Forward-Looking Information Cautionary Statement

This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). Forward looking statements in this release includes, but is not limited to, statements about the future legalization of recreational cannabis and cannabis-infused products in Canada, statements about future research, development and innovation by the Company, statements about the offering of any particular products by the Company and statements regarding the future performance of the Company. Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of Toronto Stock Exchange) accept responsibility for the adequacy or accuracy of this release.

Source: GlobeNewswire (June 11, 2018 – 8:14 AM EDT)

VANCOUVER, British Columbia, June 11, 2018 (GLOBE NEWSWIRE) — Naturally Splendid Enterprises Ltd.(“Naturally Splendid”, “NSE” or “the Company”) (FRANKFURT:50N) (TSX-V:NSP) (OTC:NSPDF) is pleased to announce that it has signed an agreement with a leading national food company for a bar/snack manufacturing contract worth up to $5 million CDN over a 5-year period through its wholly owned subsidiary, Prosnack Natural Foods Inc. (“Prosnack”).

United States Snack Bar Market – Growth, Trends and Forecasts (2018 – 2023) – Increasing Demand from the Sports Sector

NSE recently acquired a new state-of-the-art bar/snack manufacturing machine which has increased the Company’s production capacity twofold, while improving on the quality of its bars and snacks. A second shift will also be added to the production schedule to accommodate increases in production needs. The new bar/snack equipment is highly-specialized and opens the door to NSE to obtain new clients that it would not have the opportunity to secure previously.  As well as increased manufacturing capacity, NSE will also be able to greatly extend its product formulation capabilities for house-brands. The equipment’s capabilities are very versatile, having the ability to produce a variety of different products for the food manufacturing industry, including various sized spheres and bars that can be coated with any number of flavours and ingredients.

Naturally Splendid CEO Douglas Mason states, “Securing this new manufacturing contract will provide NSE with needed revenue and access to new markets. Increasing our production capacity and product innovation capabilities was an important objective, this now gives NSE the flexibility to approach new customers and significantly add to our service offerings. We see private labelling and co-manufacturing as enormous opportunities for added revenue, we are currently in advanced discussions with other companies seeking similar manufacturing requirements.”

Naturally Splendid Executive VP Sales & Marketing Alan Maddox states, “After successfully completing the transition of Prosnack to the NSE facility in April 2018, one of our focuses was to increase production capacity to be able to meet the demand for larger clients’ requirements. Acquiring this new machinery has supported us in this objective. The production interruption Prosnack experienced with the transition to the NSE facility near the end of Q4 2017 and in Q1 2018 is now behind us and we are actively seeking more commitments from previous and new clients.”

A report published by MarketResearch.biz on May 30^th, 2018, concludes: “The global snack bar market is expected to grow significantly in the coming years. The major factors contributing to the growth of the market include increasing demand of high-protein snack bars, consumers’ daily snacking habits and demands for protein and fibre ingredients that they look for in snack bars.  In addition, there is a rising demand for vegan snack bars as consumers who lead a vegan lifestyle opt for healthy substitutes for meat, dairy and other conventional sources of protein.”

“The market in North America is expected to dominate the global snack bars market owing to living standards coupled with high disposable income. The market in Asia Pacific is expected to register a highest CAGR in the forthcoming years. Snack bars are considered trending options for consumers who prefer on-the-go breakfast and portable and convenient snacking options.”

Increasing Demand from the Sports Sector – published by Mordor Intelligence on December 2017.

Brands are becoming more specific regarding the type of athletic support they provide, by targeting defined segments of the overall sports experience, from preparation to recovery. Energy and endurance bars maintain blood-glucose levels during exercise, and contain a high concentration of carbohydrates, with typically moderate amounts of protein and fat. Balanced bars have very evenly balanced nutritional profiles, which contain similar proportions of carbohydrates, protein, and fat. Protein bars in the United States are targeted at bodybuilders, to help them achieve their muscle mass and strength goals. Consumers of sports nutrition products have been bodybuilders and athletes. This trend is changing, as weekend sports enthusiasts and lifestyle users are creating new market opportunities for snack bar manufacturers.

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/3a7279b8-c27f-42c5-b470-f6080507d4f8

Private Placement

Naturally Splendid is also pleased to announce the terms of a private placement for up to $1.26 million comprising of up to 7,000,000 units (each a “Unit”) at a price of $0.18 per Unit (the “Offering”).

Each Unit offered will be comprised of one common share of Naturally Splendid and one-half of one common share purchase warrant (“Warrant”), with each whole Warrant entitling the holder to purchase one additional common share at $0.27 per share for a period of two years from the date of the issue.  Naturally Splendid will have the right to accelerate the expiry date of the Warrants if, at any time, the average closing price of Naturally Splendid’s common shares is equal to or greater than $0.35 for 10 consecutive trading days.  In the event of acceleration, the expiry date will be accelerated to a date that is 30 days after Naturally Splendid issues a news release announcing that it has elected to exercise this acceleration right.

There is no minimum amount to the Offering.  The Offering will be completed to “accredited investors” pursuant to National Instrument 45-106 – Prospectus and Registration Exemptions (“NI 45-106”), to existing security holders pursuant to BC Instrument 45-534 – Exemption from prospectus requirement from certain trades to existing security holders (“BCI 45-534”) and to certain subscribers pursuant to B.C. Instrument 45-536 – Exemptions from prospectus requirement for certain distributions through an investment dealer.  The Offering of securities pursuant to BCI 45-534 is being made to existing security holders who held shares of Naturally Splendid on June 7, 2018 (the “Record Date”).  Naturally Splendid confirms that there is no material fact or material change regarding Naturally Splendid that has not been generally disclosed.  In the event that Naturally Splendid receives subscriptions above the maximum, Naturally Splendid will adjust the subscriptions received on a pro-rata basis.

Proceeds of the Offering will be used for expansion of Naturally Splendid’s existing facilities and working capital purposes.  Naturally Splendid may pay finders a finder’s fee in cash and/or share purchase warrants.  Closing of the private placement is subject to TSX Venture Exchange approval.

The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended, (the “U.S. Securities Act”) or any state securities laws, and accordingly, may not be offered or sold within the United States except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities requirements or pursuant to exemptions therefrom. This news release does not constitute an offer to sell or a solicitation of an offer to buy any of Naturally Splendid’s securities in the United States.

About Naturally Splendid Enterprises Ltd.

Naturally Splendid is a biotechnology and consumer products company that is developing, and we are producing, commercializing, and licensing an entirely new generation of plant-derived, bioactive ingredients, nutrient dense foods, and related products. Naturally Splendid is building an expanding portfolio of patents (issued and pending) and proprietary intellectual property focused on the commercial uses of industrial hemp and non-psychoactive cannabinoid compounds in a broad spectrum of applications.

Naturally Splendid currently has four innovative divisions:

(1) BIOTECHNOLOGY –  Focused on three major platforms:

1. Proprietary HempOmega™ encapsulation
2. Extraction and formulation with Cannabidiol (CBD)
3. Hemp and plant-based proteins.

(2) CONSUMER PRODUCTS –

• NATERA® – brand of retail hemp and superfood products distributed throughout North America, Asia and Europe.
• Prosnack Natural Foods Inc. (Elevate Me™) – lifestyle brand of healthy meal replacement products distributed throughout North America.
• Chi Hemp Industries Incorporated (CHII) – e-commerce platform for natural and organic hemp products.
• PawsitiveFX® – topical pet care products.
• NATERA®CBD – retail hemp-based cannabinoid nutraceutical and cosmeceutical products distributed in Asia.
• NATERA®Skincare – brand of retail hemp based cosmeceutical products.

(3) NATERA® Ingredients – bulk ingredients including HempOmega™.

• ACI Foods is a science-based, industrial hemp seed processing business located in Abbotsford, BC. Listed as the only strictly organic hemp seed processor in North America.

(4) Co-Packaging/Toll-Processing and Manufacturing – packaging for house-brands (NATERA®, CHII™ and Elevate Me™) and third-party partners.

For more information e-mail info@naturallysplendid.com or call Investor Relations at 604-673-9573

On Behalf of the Board of Directors

Mr. Douglas Mason
CEO, Director

Contact Information

Naturally Splendid Enterprises Ltd.
(NSP – TSX Venture; NSPDF – OTCQB; 50N Frankfurt)
#108-19100 Airport Way
Pitt Meadows, BC, V3Y 0E2
Office:  (604) 465-0548
Fax:      (604) 465-1128
E-mail: info@naturallysplendid.com
Website: www.naturallysplendid.com

Forward-Looking Statements

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. Naturally Splendid cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond Naturally Splendid’s control including, Naturally Splendid’s ability to compete with large food and beverage companies; sales of any potential products developed will be profitable; sales of shelled hemp seed will continue at existing rates or increase; customers will complete on sales contracts; and the risk that any of the potential applications may not receive all required regulatory or legal approval. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, Naturally Splendid undertakes no obligation to publicly update or revise forward-looking information.

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Source: GlobeNewswire (June 11, 2018 – 5:00 AM EDT)

Toronto, Ontario–(Newsfile Corp. – June 8, 2018) – RISE Life Science Corp. (CSE: RLSC) (the “Company” and/or “RISE”), today provided an operational update on its plans and projected timelines for the 2018 calendar year. RISE is pleased to announce that it expects to launch its own commercial products for sale in the California market on or about its previously announced launch date of 6/20/2018.

“With the recent introduction of the RISE Report on SEX and Cannabis our longitudinal cannabis and sex study, followed by the launch of our digital publication, RISE Mag (http://riselifescience.com/rise-mag/), which just completed featured coverage of the recent Lift event in Toronto, we have already executed against a number of key milestones,” said Anton Mattadeen, CEO of RISE. “In this activity update we are pleased to share that our targeted product rollout in the California market is on schedule. It will begin with our suite of CBD sexual health products, followed by CBD topical products in early calendar Q3 2018, coinciding with the launch of our full CBD suite of sexual health products in other legal jurisdictions. The Company is also planning a CBD-based beverage line of products in multiple markets within the next 12 months.”

RISE products are expected to be available in California retail locations by the end of July and will be offered through dispensaries initially, followed by health food retailers and natural wellness boutiques. Chris Dollard, COO of RISE stated that “Addressing sexual health and wellness is a deeply personal decision that requires both excellent communication protocols and discretion. We want the retail experience to be comfortable, enlightening, and above all – fun. Communicating the right information in the right way is a key process for us and the main reason why we are so selective about our retail partnerships.”

All RISE products are designed to appeal to the conventional mass adult market. The Company is therefore planning to utilize other mainstream health and wellness retail distribution points beyond dispensaries to widen availability. Mr. Mattadeen further stated that “Our CBD baseline supported by our cannabis and sex longitudinal research study enables us to provide products and information that fits perfectly within any health and wellness retail environment, and is the only suite of CBD products supported by open, ongoing behavioral research efforts. As the importance of CBD continues to gain traction as an important product set for trusted local and national health retailers, RISE sexual health and wellness products will be well positioned to become a big part of that story.”

Longer term, the Company’s goals include establishing the capacity in 2019 to market its full spectrum of CBD products in the United States, Canada and Europe. Beyond 2019, the Company’s expansion goals include seeking marketing and manufacturing partnerships in the Asia-Pacific region, while continuing to deepen and expand its range of products.

About RISE Life Science Corp.

RISE Life Science Corp. develops cutting-edge cannabis consumer products for both medical and adult-use markets around the world in jurisdictions that have legal regulatory frameworks in place. All products are based on patent-pending formulations and processes to produce specifically targeted effects. A key area of focus for RISE is research-based formulations to address adult sexual health and wellness for both women and men.
(http://riselifescience.com)

Cautionary Statement Regarding Forward-Looking Information

The Canadian Securities Exchange has not reviewed this news release and does not accept responsibility for the adequacy or accuracy of this news release.

Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in RISE’s periodic filings with Canadian securities regulators. When used in this news release, words such as “will, could, plan, estimate, expect, intend, may, potential, believe, should, target, goals, projections, anticipated” and similar expressions, are forward- looking statements. Forward-looking statements may include, without limitation, statements including the Company’s expectations with respect to pursuing new opportunities and its future growth and other statements of fact.

Although RISE has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: general economic conditions; pending and proposed legislative or regulatory developments including the impact of changes in laws, regulations and the enforcement thereof; reliance on funding models; operational and infrastructure risks including possible equipment failure and performance of information technology systems; intensifying competition resulting from established competitors and new entrants in the businesses in which the Company operates; insurance coverage of sufficient scope to satisfy any liability claims; fluctuations in total customers; technological change and obsolescence; loss of services of key senior management personnel; privacy laws; leverage and restrictive covenants; fluctuations in cash timing and amount of capital expenditures; tax-related risks; unpredictability and volatility of the price of the Company’s securities; dilution; and future sales of the Company’s securities. Further risks include operational risks of operating in the U.S.; U.S. federal regulation risks; variation in U.S. state regulations; change of U.S. cannabis laws; security risks; risks related to permits and authorizations; risks on liability, enforcement complaints etc.; banking risks; marketing, sales, manufacturing and distribution risk regarding our product growth plans; changes in laws; limited operating history; reliance on management; requirements for additional financing; hindering market growth and state adoption due to inconsistent public opinion and perception of the medical-use and adult-use marijuana industry; and regulatory or political change. There can be no assurance that such information will prove to be accurate or that management’s expectations or estimates of future developments, circumstances or results will materialize. As a result of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events. Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. RISE disclaims any intention or obligation to update or revise such information, except as required by applicable law, and RISE does not assume any liability for disclosure relating to any other company mentioned herein.

For more information, please contact:

Mark Komonoski
Communication Director, RISE Life Science
mark@komonoski.com
877-255-8483
403-470-8384

Or:

Anton Mattadeen
President & CEO
anton@riselifescience.com
416-899-9462

Source: Newsfile Corp. (June 8, 2018 – 8:00 AM EDT)

VANCOUVER, British Columbia, June 08, 2018 (GLOBE NEWSWIRE) — Rosy Mondin, CEO of Quadron Cannatech Corporation (the “Company” or “Quadron”) – (CSE:QCC), was interviewed in a feature story from the Canadian Securities Exchange (“CSE”) this week. Ms. Mondin and three other women were noted for their powerful influence on the future of the Canadian cannabis industry.

Ms. Mondin outlined her strategic vision for the market and how she works on multiple levels to remain fully engaged in the cannabis sector. Her focus is on running the Quadron family of companies, but she continues her tireless advocacy work at the federal level, helping to shape the future of cannabis across the nation through the Cannabis Trade Alliance of Canada (“CTAC”) and Canadian Association of Medical Cannabis Dispensaries (“CAMCD”).

Quotes from the article:

On Quadron:
“Quadron Cannatech (QCC) is a market and technology leader in end-to-end automated processing and extraction laboratory solutions for the international cannabis industry. QCC also provides a range of innovative, value- added services including custom ancillary products and cannabis accessories.”

On the future of cannabis consumption:
“I think the biggest shift will be the consumption of cannabis moving away from smoking traditional flower to products that are extract-based. Extracts form the basis of the majority of cannabis products outside of smoking: vapor-oils, capsules, tinctures, sublinguals, transdermal patches, edibles, topicals, suppositories, and infused beverages. I have no doubt that we’ll see different consumption methods and further product innovation. I think the sky’s the limit.”

On advocacy:
“This is a 21st-century industry and women can play a leadership role from day one. For example, as a business leader in a new industry, I don’t think sitting back and just accepting the regulations the government tables is acceptable. We’re getting out there and helping define the rules as the country moves forward.”

The Company would like to congratulate Ms. Mondin on the CSE’s recognition of the unique skills and experience in the Canadian cannabis industry she brings to our leadership team.

About Quadron: Quadron, provides equipment, products and service solutions for the authorized cannabis industry by providing a full array of end-to-end extraction and processing solutions, including sales of end user delivery options (such as vapor pens) for medical and recreational consumers.

For more information, visit: www.quadroncannatech.com.

On behalf of the Board of Directors of
QUADRON CANNATECH CORPORATION

Doug McFaul
Chairman of the Board
doug@quadroncannatech.com

Investor Relations Contact:
KIN Communications Inc.
Caleb Jeffries, VP, Investor Relations
1-866-684-6730
QCC@kincommunications.com

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as “forward-looking statements”. Forward-looking statements may be identified by words including “anticipates”, “believes”, “intends”, “estimates”, “expects” and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company’s future operations and business prospects, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements.

Source: GlobeNewswire (June 8, 2018 – 8:30 AM EDT)

Choom Holdings Inc.: Chris Bogart, President & CEO, T: 604.683.2509, F: 604.683.2506, E: chris@choom.caCopyright CNW Group 2018

Source: Canada Newswire (June 8, 2018 – 6:00 AM EDT)

Toronto, Ontario–(Newsfile Corp. – June 7, 2018) – RISE Life Science Corp. (CSE: RLSC) (the “Company” and/or “RISE”)  is pleased to announce that it has signed a Letter of Intent (LOI) to acquire 100% of Life Bloom Organics, LLC, a California company that produces and markets organic oral sprays containing CBD, and 100% of Cultivate Kind, one of the top marketing and branding agencies for the cannabis industry in the United States.

“This represents a major milestone for RISE,” said RISE CEO Anton Mattadeen. “By blending the values, talents and resources of the people behind Cultivate Kind and Life Bloom with the RISE team, we are adding significant in-market expertise and providing immediate revenue to the company, moving RISE closer to its goal of becoming a vertically integrated entity in the California market.”

Life Bloom Organics

Life Bloom Organics is based in Malibu, California. The company formulates, manufactures and sells a range of cannabis products that deliver effective pain relief without any psychoactivity. Its product line currently includes 2 SKUs: Wellness Formula and Sleep Formula, both nanotized CBD oral sprays made with proprietary formulas; Life Bloom’s proprietary process of nanotizing CBD allows for 95% absorbency in the bloodstream, making it an effective aid for chronic pain, jetlag, and insomnia. Life Bloom products utilize organic, non-GMO hemp sourced from Kentucky through the Department of Agriculture Hemp program, and are compliant with Section 7606 of the 2014 Farm Bill. Life Bloom products are currently available at chiropractic offices, natural health food markets, specialty retailers, and medical marijuana dispensaries across California, as well as sold online via the brand’s e-commerce website.

The acquisition of Life Bloom by RISE will immediately expand RISE’s portfolio of CBD products, along with allowing access to Life Bloom’s existing channels of distribution and production in the United States. RISE’s acquisition will leverage Life Bloom’s retail network to facilitate the launch of additional RISE brands in market, and Life Bloom’s proprietary process of nanotizing CBD for increased bioavailability without psychoactivity will be also be utilized for future complementary products under the RISE brand umbrella. RISE and Life Bloom Organics believe the partnership integrates the best products in the markets, ringing true with the California cannabis credo of collaboration, not competition.

Cultivate Kind

Cultivate Kind brings a vertically integrated infrastructure and years of strong agency experience to support RISE in launching lifestyle brands in the cannabis space. They were brought on board as an agency partner to help RISE launch its CBD-based sexual wellness brand; once the two companies began working together, it became clear that Cultivate Kind’s capabilities augment the RISE team in its aim to quickly become a leading cannabis brand house.

The current Cultivate Kind company ecosystem includes a network of best-in-class production resources, enabling it to provide clients with the very best support for new and established brands; the agency has recently brought CBD company Life Bloom Organics to market with great success in California. The Malibu-based agency brings Canada’s RISE team top-flight strategic marketing talent and a network of successful business partnerships, retail relationships and production resources in the United States, and is intended to provide RISE with the foundation to efficiently launch its new brands in US markets, facilitate rapid market penetration and national growth, and leverage the full talent pool for global growth moving forward.

Terms

Under the terms of the agreement, RISE will issue 2,000,000 common shares in aggregate to the sellers of Life Bloom Organics and Cultivate Kind. The common shares will be subject to the following contractual lockup provisions: (i) for the first 12 months from closing, 100% of the payment shares will be subject to lock-up; (ii) after 12 months, 75% of the payment shares will be remain subject to lock-up; (iii) after 24 months, 50% of the payment shares will remain subject to lock-up; and (iv) after 36 months, no payment shares will be subject to lock-up. In addition, warrants to purchase 1,000,000 common shares in RISE will be issued at closing, each warrant having a five year term and an exercise price no less than the market price of the common shares at closing, and such other terms as may be negotiated prior to closing. The sellers of Life Bloom Organics and Cultivate Kind will be paid aggregate cash consideration of US$175,000 at closing, US$162,500 on June 1, 2019 and US$162,500 on June 1, 2020. Certain principals of the companies will be offered employment contracts with RISE’s U.S. subsidiary.

The acquisition is subject to a number of conditions, including completion of due diligence and finalizing the terms of the definitive purchase agreement. There can be no assurance that the acquisition of Life Bloom Organics and Cultivate Kind will be completed as proposed, or at all.

About RISE Life Science Corp.

RISE Life Science Corp. develops cutting-edge cannabis consumer products for both medical and adult-use markets around the world in jurisdictions that have legal regulatory frameworks in place. All products are based on patent-pending formulations and processes to produce specifically targeted effects. A key area of focus for RISE is research-based formulations to address adult sexual health and wellness for both women and men.

(http://riselifescience.com)

About Life Bloom Organics

Life Bloom Organics produces and markets nanotized, hemp-based CBD wellness and sleep aid oral sprays with non-GMO, all natural ingredients. The company is headquartered in Malibu, and all products are formulated and produced in California. Life Bloom Organics products are available for sale online and at retailers throughout southern California.

(https://lifebloomorganics.com/)

About Cultivate Kind

Brand strategy agency Cultivate Kind specializes in full-service brand development, go-to-market strategy, and retail marketing. Headquartered in Malibu, California, the executive team specializes in brand pathfinding with an extensive background in food and beverage, consumer products, wine and spirits, fashion and retail, automotive, and entertainment, which informs the company’s best practices and tactical programs for new consumer brands.

(https://www.cultivatekind.com/)

Cautionary Statement Regarding Forward-Looking Information

The Canadian Securities Exchange has not reviewed this news release and does not accept responsibility for the adequacy or accuracy of this news release.

Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in RISE’s periodic filings with Canadian securities regulators. When used in this news release, words such as “will, could, plan, estimate, expect, intend, may, potential, believe, should, target, goals, projections, anticipated” and similar expressions, are forward- looking statements. Forward-looking statements may include, without limitation, statements including the Company’s expectations with respect to pursuing new opportunities and its future growth and other statements of fact.

Although RISE has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: general economic conditions; pending and proposed legislative or regulatory developments including the impact of changes in laws, regulations and the enforcement thereof; reliance on funding models; operational and infrastructure risks including possible equipment failure and performance of information technology systems; intensifying competition resulting from established competitors and new entrants in the businesses in which the Company operates; insurance coverage of sufficient scope to satisfy any liability claims; fluctuations in total customers; technological change and obsolescence; loss of services of key senior management personnel; privacy laws; leverage and restrictive covenants; fluctuations in cash timing and amount of capital expenditures; tax-related risks; unpredictability and volatility of the price of the Company’s securities; dilution; and future sales of the Company’s securities. Further risks include operational risks of operating in the U.S.; U.S. federal regulation risks; variation in U.S. state regulations; change of U.S. cannabis laws; security risks; risks related to permits and authorizations; risks on liability, enforcement complaints etc.; banking risks; marketing, sales, manufacturing and distribution risk regarding our product growth plans; changes in laws; limited operating history; reliance on management; requirements for additional financing; hindering market growth and state adoption due to inconsistent public opinion and perception of the medical-use and adult-use marijuana industry; and regulatory or political change. There can be no assurance that such information will prove to be accurate or that management’s expectations or estimates of future developments, circumstances or results will materialize. As a result of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events. Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. RISE disclaims any intention or obligation to update or revise such information, except as required by applicable law, and RISE does not assume any liability for disclosure relating to any other company mentioned herein.

For more information, please contact:

Mark Komonoski
Communication Director, RISE Life Science
mark@komonoski.com
877-255-8483
403-470-8384

Or:

Anton Mattadeen
President & CEO
anton@riselifescience.com
416-899-9462

Source: Newsfile Corp. (June 7, 2018 – 8:52 AM EDT)

Scott Young, Telephone: +1.705.888.2756Copyright CNW Group 2018

Source: Canada Newswire (June 7, 2018 – 9:00 AM EDT)

VANCOUVER, British Columbia, June 07, 2018 (GLOBE NEWSWIRE) — FinCanna Capital Corp. (“FinCanna”) (CSE:CALI) (OTCQB:FNNZF) a royalty company for the U.S. licensed medical cannabis industry, announced today that Cultivation Technologies Inc., (CTI) its first investment in California, has achieved US$1 million in cumulative revenue since it commenced commercial operations in late January 2018.

FinCanna announced previously this week that CTI has expanded its network of dispensaries carrying Coachella™ Premium brand of cannabis concentrates and vape cartridges which features all the major concentrate types, including diamonds, sauce, shatter, batter, and sugar, with an ongoing list of strains, to ten locations including premium dispensaries across California.

“We are very pleased to see the sales performance of CTI which has translated into its first US$1 million in revenue at only a fraction of its capacity,” said Andriyko Herchak, President and CEO of FinCanna Capital. “With its sales team in place building out an ever-expanding distribution footprint, and it’s manufacturing ramping up we see a bright future as we move into the second half of 2018.”

CTI is working to maximize the commercial potential of its extraction facility, which can process an estimated 6,000 pounds of biomass per month, which translates to approximately 3.7 million grams of raw cannabis oil annually. FinCanna is entitled to receive 50% of the profits from this extraction facility.

CTI, through its subsidiaries, Coachella Manufacturing and Coachella Distributors, has helped pioneer cannabis “Extraction-as-a-Service” or “Contract Manufacturing” which it provides to brands, cultivators, manufacturers and distributors who require licensed Butane Hash Oil (“BHO”) processing for their biomass or contract manufacturing services for various products.

With divisions that fulfill the various levels of procurement of cannabis products, including distribution to retail dispensaries, CTI has been at the forefront of this developing industry – including meeting the complex standards required to be fully-licensed within the state.

Coachella Manufacturing is one of the first companies to operate a legal solvent extraction facility for cannabis in California. In support of safe manufacturing practises, CTI, has been actively engaged in sponsoring state legislation AB2679, which sets the standards and institutional best practises for cannabis extraction using solvents.

“We’re quite encouraged about the revenue growth CTI is experiencing in just a few short months since launching operations,” said Miguel Motta, President & CEO of Cultivation Technologies, Inc. “We’ve learned a lot about the market and expect to build upon our initial success in 2018 and beyond.”

About Cultivation Technologies

Cultivation Technologies, Inc. provides infrastructure, manufacturing, extraction, distribution, technology, and branding to the legal medical cannabis industry. The company owns 6-acres in Coachella, California, which is entitled for a 111,500+ square foot facility featuring cultivation centers, manufacturing facilities, a testing lab, a distribution hub featuring transportation, and a centralized processing center. The Company acquired temporary licenses for “Type 7” manufacturing and distribution from the State of California in January 2018. For more information, visit www.CultivationTech.com.

About FinCanna Capital Corp.

FinCanna provides financing to top-tier companies in the licensed medical cannabis industry in exchange for a royalty on revenues.  FinCanna, led by a team of finance and industry experts, is building its diversified portfolio of royalty investments in scalable, best-in-class projects and companies in U.S. legal states, with a focus on California.  For additional information visit: www.fincannacapital.com and FinCanna’s profile at www.sedar.com

FinCanna Capital Corp.
Andriyko Herchak, CEO & Director

Investor Relations:
Arlen Hansen
Kin Communications
1-866-684-6730
CALI@kincommunications.com

Forward-Looking Information

Information set forth in this news release may involve forward-looking statements under applicable securities laws. Forward-looking statements are statements that relate to future, not past, events. In this context, forward-looking statements often address expected future business and financial performance, and often contain words such as “anticipate”, “believe”, “plan”, “estimate”, “expect”, and “intend”, statements that an action or event “may”, “might”, “could”, “should”, or “will” be taken or occur, or other similar expressions. All statements, other than statements of historical fact, included herein including, without limitation, statements about FinCanna’s ability to source suitable projects, the development and construction of the CTI’s facility at Coachella, and the size and success of operations at the Extraction Facility and FinCanna’s ability to generate revenues therefrom.  By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the risks identified in the CSE listing statement and other reports and filings with the applicable Canadian securities regulators. Forward-looking statements are made based on management’s beliefs, estimates and opinions on the date that statements are made, and the respective companies undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable securities laws. Investors are cautioned against attributing undue certainty to forward-looking statements. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by applicable law.

Source: GlobeNewswire (June 7, 2018 – 3:05 AM EDT)

please visit the Company’s website at: www.blockstrain.io or contact Paula Arab at (403) 889-9128 or email at paula.arab@blockstrain.ioCopyright CNW Group 2018

Source: Canada Newswire (June 7, 2018 – 5:00 AM EDT)

8 Wellington St. E. Mezzanine Level, Toronto, ON, M5E 1C5, www.HighHampton.com; David E. Argudo, Chief Executive Officer, Email: david@highhampton.com, Phone: 1.844.420.CALI Or Christian Scovenna, Director & VP Corporate Finance, Email: christian@HighHampton.com, Phone: 1.844.420.CALICopyright CNW Group 2018

Source: Canada Newswire (June 7, 2018 – 8:00 AM EDT)

Source: PR Newswire (June 7, 2018 – 8:30 AM EDT)

VANCOUVER, British Columbia, June 07, 2018 (GLOBE NEWSWIRE) — Quadron Cannatech Corporation (the “Company” or “Quadron”) – (CSE:QCC), is pleased to announce that it has completed a sale of its first mobile extraction module to TLC Botanicals Inc. (TLC Botanicals), located in Langley, British Columbia.

TLC Botanicals is a First Nation holistic family-oriented company, working cooperatively with First Nations towards building and operating licensed facilities and providing medical cannabis to both First Nations and conventional patients. Shamans First Choice dispensary, a subsidiary of TLC Botanicals will provide medical cannabis to approved patients in Canada under the Access to Cannabis for Medical Purposes Regulations (ACMPR).

Quadron designs, constructs and deploys mobile extraction laboratories to service the cannabis sector. Many growers have limited square footage to build and operate a full extraction and processing facility – Quadron’s mobile extraction system is a state-of-the-art modular, self-contained and fully portable extraction and processing laboratory. Quadron’s mobile units come in different modules to accommodate the specific production needs of the client. Each module offers a scalable controlled-environment, which takes up a limited footprint, and is shipped on-site and installed in less than a day.

Rosy Mondin, CEO of Quadron states, “Through innovative engineering, and by leveraging our extraction and processing knowledge and expertise, we’ve designed a turn-key, drop in place, fully-functioning extraction environment. The end-result is a processing solution that serves a growing demand within the cannabis industry, enabling participants to process plants for terpenes and other cannabis compounds in a safe and professional setting.”

Dave Campbell, General Manager and Director of TLC Botanicals states: “It was a pleasure working alongside the Quadron team in the purchase of our new extraction unit. The professionalism they showed us was evident as they took our customized order and made the necessary adjustments to maximize the production levels we require. We look forward to future dealings with Quadron and its great team.”

About Quadron: Quadron, provides equipment, products and service solutions for the authorized cannabis industry by providing a full array of end-to-end extraction and processing solutions, including sales of end user delivery options (such as vapor pens) for medical and recreational consumers.

For more information, visit: www.quadroncannatech.com

On behalf of the Board of Directors of
QUADRON CANNATECH CORPORATION

Rosy Mondin
CEO
rosy@quadroncannatech.com

Investor Relations Contact:
KIN Communications Inc.
Caleb Jeffries, VP, Investor Relations
1-866-684-6730
QCC@kincommunications.com

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as “forward-looking statements”.  Forward-looking statements may be identified by words including “anticipates”, “believes”, “intends”, “estimates”, “expects” and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company’s future operations and business prospects, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements.

Source: GlobeNewswire (June 7, 2018 – 8:30 AM EDT)

Los Angeles, CA – June 6, 2018 – MedMen Enterprises Inc. (CSE: MMEN) (“MedMen”), the country’s leading cultivator, producer and retailer of state-sanctioned cannabis, today announced that it has signed a definitive agreement (the “Agreement”) to acquire dispensary and cultivation assets from Florida based Treadwell Simpson Partnership and affiliates (“Treadwell Nursery”).

As part of the transaction, MedMen will acquire Treadwell Nursery’s cultivation facility situated on 5 acres in Eustis, Florida and the right to open 25 medical marijuana dispensaries in the State of Florida.

“For nearly a decade we have been positioning ourselves to capitalize on enormous market opportunities like this,” said MedMen Co-founder and CEO Adam Bierman. “This acquisition is right in line with our strategy of establishing a presence early on in high potential markets with limited licenses and large populations. Florida is the third most populous state in the country with a medical marijuana market estimated to reach $1 billion in annual sales by 2020. MedMen has built the best-in-class brand, and we continue to invest in premium assets that solidify our dominant position in the most important cannabis markets in the world.”

MedMen employs more than 800 people and currently operates 18 licensed cannabis facilities in cultivation, manufacturing and retail in California, Nevada and New York. The addition of Florida expands the Company’s reach to yet another key market in the fastest growing industry in the country.

As consideration for the acquisition, the Company will pay US$53 million, subject to a working capital adjustment, half of which will be satisfied in cash and the other half of which will be satisfied by way of issuance of common units of MM Enterprises USA, LLC (the “LLC”), a subsidiary of the Company (the “Redeemable Units”), which by their terms are redeemable for Class B Subordinate Voting Shares of the Company (the “Subordinate Voting Shares”). In respect of the cash consideration, the LLC will pay Treadwell Nursery US$6,625,000 on the closing date and on each of the dates that are three (3), six (6) and nine (9) months after the closing date. In respect of the Redeemable Units, the number of units will be based on the lesser of the closing trading price of the Subordinate Voting Shares on the Canadian Securities Exchange as of June 4, 2018 or the two-week weighted average daily closing price prior to the closing of the transaction.

The transaction is expected to close within 90 days and is subject to customary closing conditions, including receipt of state regulatory approvals. If certain regulatory approvals are not obtained, the Company and Treadwell Nursery will have the right to terminate the Agreement.

Conference Call/Presentation

MedMen management will host a conference call, which will be webcast live, on Thursday, June 7, 2018 at 9:00 a.m. EST to discuss the acquisition. Participation details and a slide presentation about the transaction will be available on the investor section of the Company’s website at www.medmen.com shortly.

About MedMen

MedMen is the preeminent cannabis Company in the United States with multiple assets and operations in California, Nevada and New York, which combined account for nearly half of North America’s addressable legal market. MedMen owns and operates licensed cannabis facilities in cultivation, manufacturing and retail, and is one of the most well recognized cannabis brands in the world today. Headquartered in Los Angeles, MedMen employs more than 800 people across the United States. The predecessor to MedMen was founded in 2010 by Adam Bierman and Andrew Modlin, two visionary entrepreneurs who saw not just a tremendous business opportunity in the growing legalization of marijuana, but a chance to re-define our society’s relationship with cannabis. MedMen supports sensible, clear and just drug laws. The Company is the single largest financial supporter of progressive marijuana laws at the local, state and federal levels, giving directly to pro-legalization groups, industry organizations and political candidates. For more information, visit http://www.medmen.com or follow us on Facebook, Twitter or Instagram.

Cautionary Note Regarding Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only MedMen’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of MedMen’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”. The forward-looking information and forward-looking statements contained herein may include, but are not limited to, information concerning the proposed acquisition, expectations regarding whether the proposed acquisition will be consummated, including whether conditions to the consummation of the proposed acquisition will be satisfied and whether the proposed acquisition will be completed on the current terms, the timing for completing the proposed acquisition, expectations for the effects of the proposed acquisition or the ability of the Company to successfully achieve business objectives, expectations regarding the Florida cannabis market and expectations for other economic, business, and/or competitive factors.

By identifying such information and statements in this manner, MedMen is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of MedMen to be materially different from those expressed or implied by such information and statements. In addition, in connection with the forward-looking information and forward-looking statements contained in this press release, MedMen has made certain assumptions. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information and statements are the following: the ability to consummate the proposed acquisition; the ability to obtain requisite regulatory approvals and third party consents and the satisfaction of other conditions to the consummation of the proposed acquisition on the proposed terms and schedule; the potential impact of the announcement or consummation of the proposed acquisition on relationships, including with regulatory bodies, employees, suppliers, customers and competitors; changes in general economic, business and political conditions, including changes in the financial markets; changes in applicable laws; compliance with extensive government regulation; and the diversion of management time on the proposed acquisition. Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.

Although MedMen believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and MedMen does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward-looking information and statements attributable to MedMen or persons acting on its behalf is expressly qualified in its entirety by this notice.

Source: MedMen Enterprises

View source version on businesswire.com: https://www.businesswire.com/news/home/20180606005692/en/

Source: Business Wire (June 6, 2018 – 9:00 AM EDT)

TORONTO, June 06, 2018 (GLOBE NEWSWIRE) — The Green Organic Dutchman Holdings Ltd. (the “Company” or “TGOD”) (TSX:TGOD) (US:TGODF) is pleased to announce the launch of a global division focused on the beverage industry.

Research & Development Facility

TGOD senior management has over 125 years (click here for resumes) of combined experience in the beverage industry, with international soft drink and beverage alcohol companies in Canada and the United States. The Green Organic Dutchman Beverage Division will utilize this experience to provide a strategic pathway into the cannabis market for large-scale beverage companies by way of direct investment, joint venture or other suitable opportunities.

The focus will be to create industry-leading branded products, and to supply organic base ingredients for use in global beverage brands. Similarities between the cannabis sector, beverage, beverage alcohol and consumer packaged goods industries are apparent. These industries share a focus on lean manufacturing, six sigma, financial controls, sales, distribution and low-cost high-quality environments to name a few. TGOD’s in-depth knowledge base of these critical channels can significantly increase efficiencies in the crossover from beverage to the cannabis industry.

As part of a $55 million R&D budget, TGOD is developing a 40,000 sq. ft. state-of-the-art research & development centre, including space for product development and pilot manufacturing. This facility is phase one of multiple phases within the 72-acre Valleyfield property designed to create novel and proprietary cannabinoid infused beverages. This facility will foster a first of its kind collaborative environment for joint ventures and partnerships that will create a distribution platform for domestic and international markets.

Please click here to view the facility.

TGOD Chief Executive Officer Robert Anderson. “This launch allows us to engage larger beverage companies in a very unique manner as TGOD has the facilities, ingredients and the intellectual capabilities that make us a compelling choice.”

According to the industry-leading research firm Brightfield Group, the hemp and CBD category is expected to reach sales of $1 billion in the US by 2020, driven by the natural food and beverage category. Cannabis-infused products are entering many new categories, including healthy lifestyle and natural health, and TGOD is well-positioned to be a leader in these new markets.

The global beverage industry is over $1 trillion in sales, and cannabis-infused beverages are set to explode into the mainstream. Beverages are already 11% of the US edible market and are expected to grow significantly with expansion into CBD. There is significant potential for health and wellness-based cannabinoid-infused beverages, such as CBD iced teas, juices and sports drinks.

“TGOD will utilize state-of-the-art R&D facilities, intellectual property and a leadership team with more than 125 years of CPG beverage experience. We will create unique, healthy and organic products for the recreational and medicinal markets,” states TGOD President, Csaba Reider. “We have the best access to capital, organic production capabilities and R&D resources in the world.”

On Behalf of the Board of Directors,

The Green Organic Dutchman Holdings Ltd.
Robert Anderson
Chief Executive Officer and Co-Chairman

ABOUT THE GREEN ORGANIC DUTCHMAN HOLDINGS LTD.

The Green Organic Dutchman Holdings Ltd. is a research & development company licensed under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”) to cultivate medical cannabis. The Company carries out its principal activities producing cannabis from its facilities in Ancaster, Ont., pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada) and its regulations.

The Company grows high quality, organic cannabis with sustainable, all-natural principles. TGOD’s products are laboratory tested to ensure patients have access to a standardized, safe and consistent product. TGOD has a funded capacity of 116,000 kg and is building 970,000 sq. ft. of cultivation facilities in Ontario and Quebec.

The Company has developed a strategic partnership with Aurora Cannabis Inc. (TSX:ACB) whereby Aurora has invested approximately C$78.1 million for an approximate 17.5% stake in TGOD. In addition, the Company has raised approximately C$315 million and has over 5,000 shareholders.

TGOD’s Common Shares and warrants issued under the indenture dated November 1, 2017 trade on the TSX under the symbol “TGOD” and “TGOD.WT”, respectively.

CONTACT INFORMATION

Investor Relations
Email: invest@tgod.ca
Phone: 1 (416) 900-7621

www.tgod.ca

Forward-Looking Information Cautionary Statement
This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). Forward looking statements in this release includes, but is not limited to, statements about the future legalization of recreational cannabis and cannabis-infused products in Canada, statements about the offering of any particular products by the Company and statements regarding the future performance of the Company. Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of Toronto Stock Exchange) accept responsibility for the adequacy or accuracy of this release.

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/b0429ffd-7702-466d-b00c-17b66878aac8

Source: GlobeNewswire (June 6, 2018 – 7:45 AM EDT)

VANCOUVER, British Columbia, June 06, 2018 (GLOBE NEWSWIRE) — RavenQuest BioMed Inc. (CSE:RQB) (the “Company” or “RavenQuest”) is pleased to announce that it has entered into a binding letter of intent with Western Agripharma Ltd. (“Western Agripharma”) and 0929476 B.C. Ltd. (“NumberCo”) in pursuit of a transaction involving the acquisition of all the outstanding share capital of Western Agripharma and a fifteen (15) acre parcel of land (the “Property”) held by NumberCo.

Western Agripharma is a late stage applicant with Health Canada in the development of a 125,000 square foot facility, purpose-built for the production of cannabis in Port Mellon, on British Columbia’s Sunshine Coast.  Western Agripharma also owns 23.75 % of Atlantic Cannabis Corp. which intends to build a 50,000 square foot facility and holds an additional 120 acres in early stage application on Nova Scotia’s Cape Breton Island.

Under the terms of the letter of intent, RavenQuest proposes to acquire all of the share capital in Western Agripharma and the Property in consideration for 4,335,294 common shares of RavenQuest at a deemed price of $0.85 per share.

“This acquisition adds the important British Columbia market to our growing presence in key markets across Canada.  RavenQuest will have state of the art licensed cannabis facilities in Ontario, Alberta and British Columbia, the three most dynamic cannabis markets in Canada,” stated George Robinson, CEO of RavenQuest.  “The Western Agripharma facility will produce 25,000 kilograms annually, meaning RavenQuest’s planned projects will combine to produce 51,000 kilograms annually at build out,” Robinson continued.  “As we often emphasize, our proprietary grow methodologies allow 125,000 square of grow space to feel like two or three times that footprint, when you factor in what our Orbital Gardening can produce in grams-per-square-foot.”

Kevin Smith, President & CEO of Western Agripharma, noted, “Working with RavenQuest means working with the best.  Their team of consultants brings a knowledge of facility design, grow methodology and plant science that in our experience is unparalleled anywhere in the industry.  We believe it’s important to work with those who have a scientific basis in everything they do.  RavenQuest is the leader on that front, and we are thrilled to join an organization that understands the importance of science and the cannabis plant.”

Completion of the acquisition of Western Agripharma and the Property is subject to a number of conditions, including, but not limited to, negotiation of definitive documentation in respect of the acquisitions, and the receipt of any required regulatory approvals.  The acquisitions cannot be completed until these conditions are satisfied, and there can be no assurance that either of the acquisitions will be completed at all.

About RavenQuest BioMed Inc.
RavenQuest BioMed Inc. is a diversified publicly traded cannabis company with divisions focused upon cannabis production, management services & consulting and specialized research & development.

On Behalf of the Board of Directors of
RAVENQUEST BIOMED INC.

“George Robinson”
Chief Executive Officer

For further information, please contact:
Mathieu McDonald, Corporate Communications
604-484-1230

Neither Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.

Cautionary Note Regarding Forward-Looking Statements

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including statements with respect to the proposed the acquisition of Western Agripharma and anticipated cannabis production from facilities operated by the Company.  The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes.  By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved.  These risks and uncertainties include but are not limited to those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements.  The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

Source: GlobeNewswire (June 6, 2018 – 6:00 AM EDT)

Alexia Helgason, Corporate Communications, 604-674-4756 (ext. 1), Alexia@FridayNightInc.com; Brayden Sutton, Director/President & CEO, 604-674-4756 (ext. 1)Copyright CNW Group 2018

Source: Canada Newswire (June 6, 2018 – 8:30 AM EDT)

VANCOUVER, British Columbia, June 06, 2018 (GLOBE NEWSWIRE) — CROP Infrastructure Corp. (CSE:CROP) (OTCMKTS:CRXPF) (“CROP” or the “Company”) is pleased to announce the company has entered into a licensing agreement for four established cannabis brands that are currently being sold in Washington and will be available in California shortly.

HEMPIRE		EVOLUTION CANNABIS		TIFFANY CBD		TRIKOM

CROP will be sub-licensing these established brands to its tenant growers in California and Washington.

Furthermore CROP announces it has acquired 10 additional brands for license to its tenant growers as follows:

PROHIBITION GREENS		ILLUMINATI CANNABIS		HONEY BADGER BUDS
PLAYERS GREENS		DIABLO HERBS		CHOICES CANNABIS
WHITE RHINO CANNABIS		GATOR GANJA		CHE CANNABIS
		MAKAVELLI CANNABIS

CROP Infrastructure Director & CEO Michael Yorke states: “As the cannabis market grows and matures, consumers will choose brands that they trust to provide superior quality.   Having unique and established brands that we will be able to license in Washington, California, other states, and globally will be another benefit that CROP will be able to provide to its tenant growers.”

All of the company’s brands and projects can now be found on our website at www.cropcorp.com. Follow Crop on Instagram @CROPCORP and twitter @Crop_cse.

Company Contact

Michael Yorke – CEO & Director
E-mail: info@cropcorp.com
Website: www.cropcorp.com
Phone: (604) 484-4206

Disclaimer for Forward-Looking Information
Certain statements in this press release related to the Offering, the securities issuable thereunder and the Transaction are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events, and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. In addition, marijuana remains a Schedule I drug under the United States Controlled Substances Act of 1970. Although Congress has prohibited the US Justice Department from spending federal funds to interfere with the implementation of state medical marijuana laws, this prohibition must be renewed each year to remain in effect. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations.. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding the regulatory and legal framework regarding the cannabis industry in general among all levels of government and zoning; risks associated with applicable securities laws and stock exchange rules relating to the cannabis industry; risks associated with maintaining its interests in its various assets; the ability of the Company to finance operations and execute its business plan and other factors beyond the control of the Company. Such forward-looking statements should therefore be construed in light of such factors, and the Company is not under any obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

The CSE has not reviewed, approved or disapproved the content of this press release.

Source: GlobeNewswire (June 6, 2018 – 9:00 AM EDT)

Investor Relations, Email: invest@tgod.ca, Phone: 1 (416) 900-7621, www.tgod.caCopyright CNW Group 2018

Source: Canada Newswire (June 5, 2018 – 7:48 AM EDT)

Abattis Contacts: Robert Abenante, President and Chief Executive Officer; For more information, please visit Abattis’s website at: www.abattis.com or www.northernvinelabs.com; For inquiries, please contact Abattis (604) 674-8232 or at info@abattis.com; BLOCKStrain Contacts: Robert Galarza, Chief Executive Officer and Director; For further information, please visit BLOCKStrain’s website at: www.blockstrain.io or contact Paula Arab at (403) 889-9128 or by email at paula.arab@blockstrain.ioCopyright CNW Group 2018

Source: Canada Newswire (June 5, 2018 – 4:30 AM EDT)

Source: PR Newswire (June 5, 2018 – 8:30 AM EDT)